Roberto Gomez

Dr. Roberto Gomez


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2013 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RGRoberto Gomez
Roberto Gomez
CBChitralekha Bhattacharya
Chitralekha Bhattacharya
NGNandita Ganesh
Nandita Ganesh
LBLisa Bailey
Lisa Bailey
PBPer Basse
Per Basse
VLVera Levina
Vera Levina
Ionizing radiation (IR) is used for patients diagnosed with unresectable non small cell lung cancer (NSCLC), however radiotherapy remains largely palliative due to radioresistance. Cancer stem cells (CSCs), as well as epithelial-mesenchymal transition (EMT), may contribute to drug and radiation resistance mechanisms in solid tumors. Here we investigated the molecular phenotype of A549 and H460 NSCLC cells that survived treatment with IR (5Gy) and are growing as floating tumor spheres and cells that are maintained in a monolayer after irradiation. Non-irradiated and irradiated cells were collected after one week, seeded onto ultra low attachment plates and propagated as tumor spheres. Bulk NSCLC cells which survived radiation and grew in spheres express cancer stem cell surface and embryonic stem cell markers and are able to self-renew, and generate differentiated progeny. These cells also have a mesenchymal phenotype. Particularly, the radiation survived sphere cells express significantly higher levels of CSC markers (CD24 and CD44), nuclear β-catenin and EMT markers (Snail1, Vimentin, and N-cadherin) than non-irradiated lung tumor sphere cells. Upregulated levels of Oct-4, Sox2 and beta-catenin were detected in H460 cells maintained in a monolayer after irradiation, but not in radiation survived adherent A459 cells. PDGFR-beta was upregulated in radiation survived sphere cells and in radiation survived adherent cells in both A549 and H460 cell lines. Combining IR treatment with axitinib or dasatinib, inhibitors with anti-PDFGR activity, potentiates the efficacy of NSCLC radiotherapy in vitro. Our findings suggest that radiation survived cells have a complex phenotype combining the properties of CSCs and EMT. CD44, SNAIL and PDGFR-beta are dramatically upregulated in radiation survived cells and might be considered as markers of radiotherapy response in NSCLC.

30 November 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NGNeal R. Godse
Neal R. Godse
NKNayel Khan
Nayel Khan
ZYZachary A. Yochum
Zachary A. Yochum
RGRoberto Gomez
Roberto Gomez
CKCarolyn Kemp
Carolyn Kemp
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Purpose: TMEM16A is a calcium-activated chloride channel that is amplified in a variety of cancers, including 30% of head and neck squamous cell carcinomas (HNSCCs), raising the possibility of an anti-apoptotic role in malignant cells. This study investigated this using a multimodal, translational investigation. Experimental Design: Combination of (i) in vitro HNSCC cell culture experiments assessing cell viability, apoptotic activation, and protein expression (ii) in vivo studies assessing similar outcomes, and (iii) molecular and staining analysis of human HNSCC samples. Results: TMEM16A expression was found to correlate with greater tumor size, increased Erk 1/2 activity, less Bim expression, and less apoptotic activity overall in human HNSCC. These findings were corroborated in subsequent in vitro and in vivo studies and expanded to include a cisplatin-resistant phenotype with TMEM16A overexpression. A cohort of 41 patients with laryngeal cancer demonstrated that cases that recurred after chemoradiation failure were associated with a greater TMEM16A overexpression rate than HNSCC that did not recur. Conclusions: Ultimately, this study implicates TMEM16A as a contributor to tumor progression by limiting apoptosis and as a potential biomarker of more aggressive disease. Clin Cancer Res; 23(23); 7324–32. ©2017 AACR.

27 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
RGRoberto Gomez
Roberto Gomez
MEMichael W. Epperly
Michael W. Epperly
Hong WangHong Wang
Hong Wang
DPDavid A. Proia
David A. Proia
JGJoel S. Greenberger
Joel S. Greenberger
VLVera Levina
Vera Levina
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Roberto Gomez-Casal1, 2, Michael W. Epperly1, 3, Hong Wang1, 4, David A. Proia5, Joel S. Greenberger1, 3, Vera Levina1, 2, † 1The University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA 2Department of Medicine, the University of Pittsburgh, Pittsburgh, PA, USA 3Department of Radiation Oncology, the University of Pittsburgh, Pittsburgh, PA, USA 4Department of Biostatistics, the University of Pittsburgh, Pittsburgh, PA, USA 5Synta Pharmaceuticals Corp., Lexington, MA, USA †Current address: Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA Correspondence to: Vera Levina, e-mail: levinav@upmc.edu Keywords: lung adenocarcinoma, fractionated ionizing radiation, radioresistance mechanisms, DNA repair, heat shock protein-90 Received: August 14, 2015 Accepted: October 14, 2015 Published: October 27, 2015

14 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AVAvani Vyas
Avani Vyas
RGRoberto Gomez
Roberto Gomez
SCSilvia Cruz-Rangel
Silvia Cruz-Rangel
HVHugo Villanueva
Hugo Villanueva
ASAndrew G. Sikora
Andrew G. Sikora
UDUmamaheswar Duvvuri
Umamaheswar Duvvuri
Significance: Cisplatin is the first line therapy for patients with head and neck cancer. However, resistance to cisplatin remains a major concern. High expression of the calcium-activated chloride channel TMEM16A in tumors portends poor survival in these patients, possibly because of drug resistance. Here, we show that TMEM16A drives the sequestration of cisplatin into lysosomes. Subsequently, cisplatin is expelled via the delivery of lysosomes to the cell surface. We show that TMEM16A enhances this process, thereby promoting cisplatin resistance. We also show that lysosomal inhibition synergizes with cisplatin to induce tumor cell death. Our data uncovers a new fundamental feature of both lysosomal physiology and cancer cell biology that can potentially impact the treatment of patients with head and neck cancer.

22 May 2015 in Cancers
Verified
Journal Article
Open access
PDF file
RGRoberto Gomez
Roberto Gomez
CBChitralekha Bhattacharya
Chitralekha Bhattacharya
MEMichael W. Epperly
Michael W. Epperly
PBPer H. Basse
Per H. Basse
Hong WangHong Wang
Hong Wang
VLVera Levina
Vera Levina
The molecular chaperone HSP90 is involved in stabilization and function of multiple client proteins, many of which represent important oncogenic drivers in NSCLC. Utilization of HSP90 inhibitors as radiosensitizing agents is a promising approach. The antitumor activity of ganetespib, HSP90 inhibitor, was evaluated in human lung adenocarcinoma (AC) cells for its ability to potentiate the effects of IR treatment in both in vitro and in vivo. The cytotoxic effects of ganetespib included; G2/M cell cycle arrest, inhibition of DNA repair, apoptosis induction, and promotion of senescence. All of these antitumor effects were both concentration- and time-dependent. Both pretreatment and post-radiation treatment with ganetespib at low nanomolar concentrations induced radiosensitization in lung AC cells in vitro. Ganetespib may impart radiosensitization through multiple mechanisms: such as down regulation of the PI3K/Akt pathway; diminished DNA repair capacity and promotion of cellular senescence. In vivo, ganetespib reduced growth of T2821 tumor xenografts in mice and sensitized tumors to IR. Tumor irradiation led to dramatic upregulation of β-catenin expression in tumor tissues, an effect that was mitigated in T2821 xenografts when ganetespib was combined with IR treatments. These data highlight the promise of combining ganetespib with IR therapies in the treatment of AC lung tumors.

8 April 2016 in Oncotarget
Verified
Journal Article
Open access
ZZZhan Zhang
Zhan Zhang
LLLing Liu
Ling Liu
RGRoberto Gomez
Roberto Gomez
XWXinhui Wang
Xinhui Wang
RHRyo Hayashi
Ryo Hayashi
ADAlbert B. DeLeo
Albert B. DeLeo
Targeting cancer stem cells with p53 modulators